Chemoresistance: Impact of Nuclear Factor (NF)-κB Inhibition by Small Interfering RNA

Resistance of cancer cells to powerful chemotherapeutic drugs has been an area of intense investigation. Efforts to understand the mechanisms underlying chemoresistance have led to significant progress toward our understanding of signaling pathways that favor cancer cell survival. Now that many

[1]  R. Gaynor,et al.  Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 Subunit , 2004, Clinical Cancer Research.

[2]  M. Cortés,et al.  ATM and the Catalytic Subunit of DNA-Dependent Protein Kinase Activate NF-κB through a Common MEK/Extracellular Signal-Regulated Kinase/p90rsk Signaling Pathway in Response to Distinct Forms of DNA Damage , 2004, Molecular and Cellular Biology.

[3]  Alan M Gewirtz,et al.  Progress in the Development of Nucleic Acids Therapeutics for Cancer , 2004, Cancer biology & therapy.

[4]  Richard Pazdur,et al.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.

[5]  I. Verma,et al.  IκB Kinase-Independent IκBα Degradation Pathway: Functional NF-κB Activity and Implications for Cancer Therapy , 2003, Molecular and Cellular Biology.

[6]  Yang Shi,et al.  Small RNA: can RNA interference be exploited for therapy? , 2003, The Lancet.

[7]  A. Hoffmann,et al.  CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response , 2003 .

[8]  R. Schmid,et al.  Mitogenic and antiapoptotic role of constitutive NF‐κB/Rel activity in pancreatic cancer , 2003, International journal of cancer.

[9]  N. Perkins,et al.  p53- and Mdm2-Independent Repression of NF-κB Transactivation by the ARF Tumor Suppressor , 2003 .

[10]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[11]  J. Adams.  Potential for proteasome inhibition in the treatment of cancer. , 2003, Drug discovery today.

[12]  W. Zong,et al.  Mechanisms of constitutive NF‐κB activation in human prostate cancer cells , 2002, The Prostate.

[13]  M. Karin,et al.  Missing Pieces in the NF-κB Puzzle , 2002, Cell.

[14]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[15]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[16]  A. Pardee,et al.  The nuclear factor kappa B (NF-κB): A potential therapeutic target for estrogen receptor negative breast cancers , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. S. Lind,et al.  Nuclear factor-κB is upregulated in colorectal cancer , 2001 .

[18]  Jingqing Yang,et al.  Constitutive IκB Kinase Activity Correlates with Nuclear Factor-κB Activation in Human Melanoma Cells , 2001 .

[19]  J. Cusack,et al.  Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. , 2000, Cancer research.

[20]  C. Van Waes,et al.  The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. , 1999, Cancer research.

[21]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[22]  G. Sledge,et al.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.

[23]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[24]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[25]  M. Read,et al.  Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the NF-B p 65 Subunit , 2004 .

[26]  Michael Karin,et al.  The IKK NF-kappa B system: a treasure trove for drug development. , 2004, Nature reviews. Drug discovery.

[27]  Douglas B. Evans,et al.  Function of Nuclear Factor κB in Pancreatic Cancer Metastasis , 2003 .

[28]  Céline Gélinas,et al.  To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis. , 2003, Oncogene.

[29]  Douglas B. Evans,et al.  Function of nuclear factor kappaB in pancreatic cancer metastasis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  N. Perkins,et al.  p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. , 2003, Molecular cell.

[31]  A. Hoffmann,et al.  CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. , 2003, Molecular cell.

[32]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[33]  S. Alkan,et al.  Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. , 2001, British journal of haematology.

[34]  A. Richmond,et al.  Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. , 2001, Cancer research.

[35]  A. Pardee,et al.  The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[37]  C. Y. Wang,et al.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. , 1996, Science.